Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02935543 · ClinicalTrials.gov registry record · Phase 2
CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
A Phase 2 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02935543: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT02935543 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02935543, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a single center, single arm, open-label phase 2 study to determine the efficacy of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART19" cells) in adults with minimal residual disease (MRD) during upfront treatment for CD19+ acute lymphoblastic leukemia.
Primary Outcome
The incidence of conversion of minimal residual disease (MRD) to \<0.01% after CART19 therapy in patients with MRD+ ALL during upfront treatment
Interventions
- BIOLOGICAL CART 19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-12-12 |
| Phase | Phase 2 |
Why NCT02935543 stopped before completion
NCT02935543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which CART 19 is the first listed.
NCT02935543 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02935543 about?
NCT02935543 is a clinical study titled "CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL". This is a single center, single arm, open-label phase 2 study to determine the efficacy of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART19" cells) in adults with minimal residual disease (MRD) ...
What is the current status of trial NCT02935543?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-10. Estimated completion is 2018-12-12.
What interventions are being tested in trial NCT02935543?
The interventions under investigation include: CART 19 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02935543?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02935543's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia